Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | F10 | P00742 | 15/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CALML3 | P27482 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13103121 | 0.89 | MAOA (0.42) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL13103196 | 0.89 | F10 (0.42) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL87717 | 0.86 | F10 (0.58) | F10 | |
| SCHEMBL14641467 | 0.86 | F10 (0.58) | F10 | |
| SCHEMBL8210167 | 0.84 | F10 (0.54) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL8210966 | 0.82 | F10 (0.51) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL13102687 | 0.76 | F10 (0.50) | MAOBF10 | |
| SCHEMBL87265 | 0.75 | F10 (0.72) | F10 | |
| SCHEMBL87238 | 0.74 | F10 (0.59) | F10 | |
| SCHEMBL13753272 | 0.74 | F10 (0.50) | MAOAMAOBF10LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | SERPINC1, SDHB, F2 | MAOA 162/4885MAOB 40/4885F10 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.